new ORAL agent for rheumatoid arthritis, Xeljanz (ZEL-jans, tofacitinib)

You'll hear about a new ORAL agent for rheumatoid arthritis, Xeljanz (ZEL-jans, tofacitinib).

Xeljanz is the first Janus kinase (JAK) inhibitor. Janus kinases are enzymes linked to inflammation in joints and other tissues.

It's not a first-line agent. It's for patients who have failed or can't tolerate methotrexate. It can also be added to methotrexate or other DMARDs...but not biologics (Humira, etc).

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 200+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote